8-K Announcements
6Material company update
Mar 25, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 2, 2026·SEC
Apogee Therapeutics, Inc.(APGE)Earnings, Financials & Key Ratios
APGE•NASDAQ
$84.54
$5.78B mkt cap·Price updated May 6, 2026
AboutApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.Show more
- Revenue$0
- EBITDA-$284M-31.1%
- Net Income-$256M-40.5%
- EPS (Diluted)-4.22-27.9%
- ROE-31.57%+5.0%
- ROIC-31.31%+18.1%
- Debt/Equity0.01-40.7%
APGE Key Insights
Apogee Therapeutics, Inc. (APGE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
APGE Price & Volume
Apogee Therapeutics, Inc. (APGE) stock price & volume — 10-year historical chart
Loading chart...
APGE Growth Metrics
Apogee Therapeutics, Inc. (APGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM100%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-27.11%
Return on Capital
10 Years-32.84%
5 Years-32.84%
3 Years-36.57%
Last Year-34.94%
APGE Recent Earnings
Apogee Therapeutics, Inc. (APGE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (55%)
Q2 2026Latest
Mar 2, 2026EPS
$1.03
Est $1.05
+1.9%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$1.11
Est $1.12
+0.9%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$1.13
Est $1.03
-9.7%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.95
Est $1.19
+20.2%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $1.03vs $1.05+1.9% | — |
| Q4 2025 | Nov 10, 2025 | $1.11vs $1.12+0.9% | — |
| Q3 2025 | Aug 11, 2025 | $1.13vs $1.03-9.7% | — |
| Q2 2025 | May 12, 2025 | $0.95vs $1.19+20.2% | — |
Based on last 12 quarters of dataView full earnings history →
APGE Peer Comparison
Apogee Therapeutics, Inc. (APGE) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 RXRX | 1.53B | 3.43 | -2.38 | 26.92% | -8.44% | -54.32% | 0.07 | |
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare APGE vs Peers
Apogee Therapeutics, Inc. (APGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APGE Income Statement
Apogee Therapeutics, Inc. (APGE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 1.42M |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.42M▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 30.73M | 93M | 216.87M | 285.6M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M | 70.88M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 27.79M | 68.42M | 167.87M | 214.71M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -30.73M▲ 0% | -93M▼ 202.7% | -216.87M▼ 133.2% | -285.6M▼ 31.7% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -202.68% | -133.19% | -31.69% |
| EBITDA | -39.78M | -83.98M | -216.68M | -284.18M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -111.1% | -158% | -31.15% |
| D&A (Non-Cash Add-back) | 0 | 9.02M | 189K | 1.42M |
| EBIT | -39.78M | -83.98M | -216.87M | -278K |
| Net Interest Income | -9.06M | 9.02M | 34.74M | 30.03M |
| Interest Income | 92K | 9.02M | 34.74M | 30.03M |
| Interest Expense | 9.15M | 0 | 0 | 0 |
| Other Income/Expense | -9.06M | 9.02M | 34.74M | 0 |
| Pretax Income | -39.78M▲ 0% | -83.98M▼ 111.1% | -182.13M▼ 116.9% | -255.56M▼ 40.3% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 18K | -278K |
| Effective Tax Rate % | 0% | 0% | -0.01% | 0.11% |
| Net Income | -39.78M▲ 0% | -83.98M▼ 111.1% | -182.15M▼ 116.9% | -255.84M▼ 40.5% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -111.1% | -116.88% | -40.46% |
| Net Income (Continuing) | -39.78M | -83.98M | -182.15M | -255.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.79▲ 0% | -1.66▼ 110.1% | -3.30▼ 98.8% | -4.22▼ 27.9% |
| EPS Growth % | - | -110.13% | -98.8% | -27.88% |
| EPS (Basic) | -0.79 | -1.66 | -3.30 | -4.22 |
| Diluted Shares Outstanding | 50.67M | 50.66M | 55.19M | 60.69M |
| Basic Shares Outstanding | 50.67M | 50.66M | 55.19M | 60.69M |
| Dividend Payout Ratio | - | - | - | - |
APGE Balance Sheet
Apogee Therapeutics, Inc. (APGE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Total Current Assets | 152.06M | 398.41M | 529.71M | 741.36M |
| Cash & Short-Term Investments | 151.89M | 395.46M | 520.65M | 730.19M |
| Cash Only | 151.89M | 118.32M | 141.79M | 131.55M |
| Short-Term Investments | 0 | 277.14M | 378.86M | 598.64M |
| Accounts Receivable | 0 | 1.21M | 4.7M | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 57K | 0 | 1.74M | 11.17M |
| Total Non-Current Assets | 0 | 3M | 224.24M | 195.78M |
| Property, Plant & Equipment | 0 | 2.59M | 13.32M | 14.38M |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 210.42M | 0 |
| Other Non-Current Assets | 0 | 401K | 498K | 181.4M |
| Total Assets | 152.06M▲ 0% | 401.4M▲ 164.0% | 753.95M▲ 87.8% | 937.13M▲ 24.3% |
| Asset Turnover | - | - | - | - |
| Asset Growth % | - | 163.99% | 87.83% | 24.3% |
| Total Current Liabilities | 9.98M | 20.56M | 28.56M | 27.91M |
| Accounts Payable | 418K | 2.14M | 1.07M | 1.22M |
| Days Payables Outstanding | - | - | - | 314.29 |
| Short-Term Debt | 0 | 1.1M | 3.23M | 3.5M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 515K | 17.15M | 22.36M | 23.18M |
| Current Ratio | 15.24x | 19.38x | 18.55x | 26.57x |
| Quick Ratio | 15.24x | 19.38x | 18.55x | 26.57x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 0 | 933K | 8.6M | 5.34M |
| Long-Term Debt | 0 | 0 | 0 | 5.34M |
| Capital Lease Obligations | 0 | 933K | 8.6M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | 9.98M | 21.49M | 37.16M | 33.25M |
| Total Debt | 0 | 2.03M | 11.83M | 8.85M |
| Net Debt | -151.89M | -116.28M | -129.96M | -122.7M |
| Debt / Equity | - | 0.01x | 0.02x | 0.01x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -3.36x | - | - | - |
| Total Equity | 142.07M▲ 0% | 379.91M▲ 167.4% | 716.79M▲ 88.7% | 903.88M▲ 26.1% |
| Equity Growth % | - | 167.4% | 88.67% | 26.1% |
| Book Value per Share | 2.80 | 7.50 | 12.99 | 14.89 |
| Total Shareholders' Equity | 142.07M | 379.91M | 716.79M | 903.88M |
| Common Stock | 2.25M | 0 | 1K | 1K |
| Retained Earnings | -39.78M | -123.77M | -305.92M | -561.76M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.14M | 329K | 915K | 1.08M |
| Minority Interest | 0 | 0 | 0 | 0 |
APGE Cash Flow Statement
Apogee Therapeutics, Inc. (APGE) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Cash from Operations | -16.43M | -74.76M | -171.17M | -227.45M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -355.11% | -128.96% | -32.88% |
| Net Income | -39.78M | -83.98M | -182.15M | -255.84M |
| Depreciation & Amortization | 0 | 0 | 189K | 1.42M |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M | 46.28M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 11.4M | -2.98M | -10.55M | -3.82M |
| Working Capital Changes | 9.81M | 6.11M | -2M | -15.48M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 418K | 1.61M | -1.07M | 150K |
| Cash from Investing | 0 | -273.91M | -300.46M | -179.57M |
| Capital Expenditures | 0 | -167K | -1.15M | -5.15M |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 168.32M | 315.39M | 495.11M | 396.49M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 1.63M | 0 |
| Net Change in Cash | 151.89M▲ 0% | -33.28M▼ 121.9% | 23.47M▲ 170.5% | -10.53M▼ 144.9% |
| Free Cash Flow | -16.43M▲ 0% | -74.93M▼ 356.1% | -172.33M▼ 130.0% | -232.6M▼ 35.0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -356.13% | -129.99% | -34.98% |
| FCF per Share | -0.32 | -1.48 | -3.12 | -3.83 |
| FCF Conversion (FCF/Net Income) | 0.41x | 0.89x | 0.94x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
APGE Key Ratios
Apogee Therapeutics, Inc. (APGE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Return on Equity (ROE) | -28% | -32.18% | -33.22% | -31.57% |
| Return on Invested Capital (ROIC) | - | -54.96% | -38.25% | -31.31% |
| Debt / Equity | - | 0.01x | 0.02x | 0.01x |
| Interest Coverage | -3.36x | - | - | - |
| FCF Conversion | 0.41x | 0.89x | 0.94x | 0.89x |
APGE SEC Filings & Documents
Apogee Therapeutics, Inc. (APGE) SEC filings — annual & quarterly reports (10-K, 10-Q)
APGE Frequently Asked Questions
Apogee Therapeutics, Inc. (APGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Apogee Therapeutics, Inc. (APGE) grew revenue by 0.0% over the past year. Growth has been modest.
Apogee Therapeutics, Inc. (APGE) reported a net loss of $255.8M for fiscal year 2025.
Dividend & Returns
Apogee Therapeutics, Inc. (APGE) has a return on equity (ROE) of -31.6%. Negative ROE indicates the company is unprofitable.
Apogee Therapeutics, Inc. (APGE) had negative free cash flow of $232.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More APGE
Apogee Therapeutics, Inc. (APGE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates